Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | APEX1 | P27695 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31090163 | 0.90 | SMN1; SMN2 (0.61) | ALDH1A1LMNAGAAHTTSMN1; SMN2 | |
| SCHEMBL20718833 | 0.90 | ALDH1A1 (0.54) | ALDH1A1LMNAGAAHTTKDM4E | |
| SCHEMBL10410570 | 0.88 | KDM4E (0.60) | ALDH1A1LMNAGAAHTTKDM4E | |
| SCHEMBL4977602 | 0.87 | ALDH1A1 (0.60) | ALDH1A1LMNAGAAHTTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11873461 | 0.86 | ALDH1A1 (0.63) | ALDH1A1LMNAGAAHTTSMN1; SMN2 | |
| SCHEMBL8973887 | 0.86 | SMN1; SMN2 (0.57) | ALDH1A1LMNAGAAHTTSMN1; SMN2 | |
| SCHEMBL8867003 | 0.86 | SMN1; SMN2 (0.57) | ALDH1A1LMNAGAAHTTSMN1; SMN2 | |
| SCHEMBL7317606 | 0.84 | SMN1; SMN2 (0.59) | ALDH1A1LMNAGAAHTTSMN1; SMN2 | |
| SCHEMBL8867007 | 0.84 | SMN1; SMN2 (0.67) | ALDH1A1LMNAGAAHTTSMN1; SMN2 | |
| SCHEMBL30135880 | 0.84 | SMN1; SMN2 (0.59) | ALDH1A1LMNAGAAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3441389-B1 | PYRAZOLE-OXAZOLIDINONE COMPOUND FOR ANTI-HEPATITIS B VIRUS | SHANGHAI ZHIMENG BIOPHARMA INC (CN) | 2021-09-08 | — | — | EP | disclosed |
| CN-109311865-B | Pyrazole-oxazolidinone compound for resisting hepatitis B virus | 上海挚盟医药科技有限公司 | 2021-08-31 | — | — | CN | disclosed |
| US-20190152963-A1 | PYRAZOLE-OXAZOLIDINONE COMPOUND FOR ANTI-HEPATITIS B VIRUS | SHANGHAI ZHIMENG BIOPHARMA, INC. (CN) | 2019-05-23 | — | — | US | disclosed |
| EP-3441389-A1 | PYRAZOLE-OXAZOLIDINONE COMPOUND FOR ANTI-HEPATITIS B VIRUS | Shanghai Zhimeng Biopharma Co., Ltd (CN) | 2019-02-13 | — | — | EP | disclosed |
| US-20180111905-A1 | N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2018-04-26 | — | — | US | disclosed |
| WO-2016167511-A2 | N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2016-10-20 | — | — | WO | disclosed |
| US-8710071-B2 | Compounds, compositions and methods for reducing lipid levels | CVI PHARMACEUTICALS LIMITED (KY) | 2014-04-29 | — | — | US | disclosed |
| US-20120004223-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS | CVI PHARMACEUTICALS LIMITED (KY) | 2012-01-05 | — | — | US | disclosed |
| US-20110009628-A1 | Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same | CVI PHARMACEUTICALS LIMITED (KY) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009628-A1 | Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same | LIPC, LDLR, PCSK9 | ALDH1A1 3512/4885LMNA 387/4885GAA 518/4885 |
| US-20190152963-A1 | PYRAZOLE-OXAZOLIDINONE COMPOUND FOR ANTI-HEPATITIS B VIRUS | HAVCR2, ZC3HAV1, ZC3HAV1L | ALDH1A1 795/4885LMNA 3781/4885GAA 3206/4885 |
| US-20180111905-A1 | N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT | ALK, NPM1, EML4 | ALDH1A1 1803/4885LMNA 744/4885GAA 3276/4885 |
| US-20120004223-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS | LIPC, LDLR, PCSK9 | ALDH1A1 2335/4885LMNA 779/4885GAA 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.